retatrutide clinical trial results 2024 2025 press release Eli Lilly just released impressive study for retatrutide, an investigational weight loss drug that targets three hormones—and may deliver more weight loss than current GLP-1s. See link below ⬇️ October 27, 2025: U.K. regulators

The company plans to resubmit the application for neffy in the first half of next year and anticipates another FDA action date in the second half of 2024

men should report severe abdominal pain or persistent vomiting to their clinician promptly

Rapid weight loss associated with retatrutide may indirectly alter skin barrier function, causing dryness or heightened sensitivity

[DOI] [PubMed] [Google Scholar] 85

PlexusDx Weight Management Protocols are billed monthly with no membership fee and no multi-month prepay lock-in a patient can stop the protocol after any month without forfeiting prepaid future months, and the Precision Peptide Genetic Test is a one-time $298 charge (or $99 add-on) rather than a recurring fee